

SUPPLEMENTARY APPENDIX

TABLE OF CONTENTS

SECTION S1: STUDY INVESTIGATORS	2
SECTION S2: PHARMACOKINETICS	3
SECTION S3: SUPPLEMENTARY METHODS	4
SECTION S4: SUPPLEMENTARY FIGURES	7
FIGURE S1. ROPINIROLE HYDROCHLORIDE REMEDY FOR AMYOTROPHIC LATERAL SCLEROSIS (ROPALS) STUDY DESIGN.....	7
FIGURE S2. MEASURED CONCENTRATION OF ROPINIROLE IN PLASMA AND CSF OVER THE ADMINISTRATION PERIOD.....	8
FIGURE S3. EFFECT OF ROPINIROLE TREATMENT ON ALSFRS-R EACH SCORE	9
FIGURE S4. CHANGES IN FOUR SUBDOMAINS OF THE ALSFRS-R SCORE (Z-SCORE) FROM BASELINE OVER 48 WEEKS.....	10
FIGURE S5. CHANGES IN MUSCLE STRENGTH, GRIP STRENGTH, AND PINCH STRENGTH (Z-SCORE) FROM BASELINE OVER 48 WEEKS.....	11
FIGURE S6. CHANGES IN %FVC, NORRIS BULBAR SCALE, TONGUE PRESSURE, BODY WEIGHT AND SERUM CREATININE (Z-SCORE) FROM BASELINE OVER 48 WEEKS.....	12
FIGURE S7. CHANGES IN ALSAQ-40 SCORES (Z-SCORE) FROM BASELINE OVER 48 WEEKS.....	13
FIGURE S8. JAPANESE ALS SEVERITY SCALE CATEGORIES OF PARTICIPANTS AT THE END OF 24 WEEKS AND 48 WEEKS.....	14
FIGURE S9A. EFFECT OF ROPINIROLE ON FERRITIN, 8-OHDG, AND HS-CRP CONCENTRATIONS OVER 48 WEEKS.....	15
FIGURE S9B. EFFECT OF ROPINIROLE ON PLASMA AND CSF NEUROFILAMENT CONCENTRATIONS OVER 48 WEEKS.....	16
FIGURE S9C. EFFECT OF ROPINIROLE ON LIPID PEROXIDATION OVER 48 WEEKS.....	17
FIGURE S10. EFFECT OF PRETREATMENT OF LOW CONCENTRATION ROPINIROLE HYDROCHLORIDE FOR ALS PHENOTYPES.....	18
FIGURE S11. THE EXPRESSION OF DOPAMINE D2 RECEPTOR IN ANTERIOR HORN CELLS OF THE HUMAN SPINAL CORD.....	20
FIGURE S12. THE EXPRESSION OF DOPAMINE D2 RECEPTOR IN HUMAN iPSC-DERIVED LOWER MOTOR NEURONS.....	21
FIGURE S13. THE TRANSITION OF ESTIMATED CHANGE IN ALSFRS-R DURING ENTIRE PERIOD FOR RR-BULBAR-, RR-NONBULBAR-, PR-BULBAR-, AND PR-NONBULBAR-ONSET GROUPS.....	22
SECTION S5: SUPPLEMENTARY TABLES	23
TABLE S1. PLASMA CONCENTRATION OF ROPINIROLE WHEN DRUG DOSE WAS INCREASED TO A MAXIMUM OF 16 MG.....	23
TABLE S2. LS MEAN CHANGE FROM BASELINE IN ALSFRS-R SCORE (FAS, DOUBLE-BLIND AND OPEN-LABEL EXTENSION PERIOD).....	24
TABLE S3. ESTIMATED RATE OF DECLINE IN ALSFRS-R SCORE AND LEVEL OF ACTIVITY OVER 48 WEEKS.....	25
TABLE S4. 95%CI FOR COMPOSITE Z-SCORE ANALYSES (RESPIRATORY FUNCTION AND MUSCLE STRENGTH).....	27
TABLE S5. 95%CI FOR COMPOSITE Z-SCORE ANALYSES (ALSFRS-R SUBDOMAINS SCORE).....	28
TABLE S6. 95%CI FOR COMPOSITE Z-SCORE ANALYSES (MUSCLE STRENGTH, GRIP STRENGTH, AND PINCH STRENGTH).....	29
TABLE S7. 95%CI FOR COMPOSITE Z-SCORE ANALYSES (ALSAQ-40 SCORES).....	30
TABLE S8. TIME-TO-DEATH OR DISEASE PROGRESSION EVENTS (ENTIRE PERIOD)	31
TABLE S9. EFFECT OF ROPINIROLE ON THE RATE OF DISEASE PROGRESSION.....	33
TABLE S10. THE LIST OF ADVERSE EFFECTS IN THE PREVIOUS PHASE 1 STUDIES OF REQUIP TABLETS IN HEALTHY INDIVIDUALS.....	34
TABLE S11. RATES OF PARTICIPANT DISPOSITION.....	35

SECTION S1: STUDY INVESTIGATORS

Name	Institution
Jin Nakahara	Department of Neurology, Keio University Hospital, Tokyo, Japan
Shinichi Takahashi	Department of Neurology, Keio University Hospital, Tokyo, Japan
Mamoru Shibata	Department of Neurology, Keio University Hospital, Tokyo, Japan
Shigeaki Suzuki	Department of Neurology, Keio University Hospital, Tokyo, Japan
Takahito Yoshizaki	Department of Neurology, Keio University Hospital, Tokyo, Japan
Daisuke Ito	Department of Neurology, Keio University Hospital, Tokyo, Japan
Yoshikane Izawa	Department of Neurology, Keio University Hospital, Tokyo, Japan
Morinobu Seki	Department of Neurology, Keio University Hospital, Tokyo, Japan
Kazutomi Kanemaru	Department of Neurology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan
Naoko Makishi	Department of Neurology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan
Rie Motoyama	Department of Neurology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan
Satoru Morimoto	Department of Neurology, Tokyo Metropolitan Geriatric Hospital and Institute of Gerontology, Tokyo, Japan
Tomohiro Hikata	Department of Orthopaedic Surgery, Kitasato University Kitasato Institute Hospital, Tokyo, Japan
Wataru Takita	Department of Neurology, National Hospital Organization Nagoya Medical Center, Aichi, Japan
Keiji Kurita	Department of Neurology, Samukawa Hospital, Samukawa Shrine, Kanagawa, Japan
Ryoji Shimoyama	Department of Neurology, National Hospital Organization Matsue Medical Center, Shimane, Japan
Kazuhiro Itaya	Department of Neurology, Ichigao Hospital, Kanagawa, Japan
Hiroaki Yokote	Department of Neurology, Nitobe Memorial Nakano General Hospital, Tokyo, Japan
Kazuhiro Ishii	Department of Neurology, Faculty of Medicine, University of Tsukuba, Ibaraki, Japan
Asuka Yasuura	Department of Neurology, Japanese Red Cross Musashino Hospital, Tokyo, Japan
Takao Ienaga	Department of Neurology, Shin-Kuki General Hospital, Saitama, Japan
Ryo Usui	Department of Neurology, Kitasato University School of Medicine, Kanagawa, Japan
Ryotaro Ikeguchi	Department of Neurology, Tokyo Women's Medical University, Tokyo, Japan
Ryuichi Ohkubo	Department of Neurology, Fujimoto General Hospital, Miyagi, Japan
Makoto Nomura	Department of Neurology, Moriya Daiichi General Hospital, Ibaraki, Japan
Hiroaki Fujita	Department of Neurology, Dokkyo Medical University, Tochigi, Japan
Risa Kato	Department of Neurology, Kansai Medical University, Osaka, Japan
Yusuke Mochizuki	Department of Neurology, Hokushin General Hospital Nagano Prefectural Federation of

	Agricultural Cooperatives for Health and Welfare, Nagano, Japan
Masahiro Kato	Department of Neurology, Medical Plaza Edogawa, Tokyo, Japan
Ban Mihara	Department of Neurology, Institute of Brain and Blood Vessels, Mihara Memorial Hospital, Gunma, Japan
Hirokazu Yoshihashi	Department of Neurology, Kobari General Hospital, Chiba, Japan
Hironobu Myojin	Department of Neurology, Seirei Hamamatsu General Hospital, Shizuoka, Japan
Takeshi Yamada	Department of Neurology, Saiseikai Fukuoka General Hospital, Fukuoka, Japan
Yuichiro Furuya	Department of Neurology, National Defence Medical College Hospital, Saitama, Japan
Konosuke Furuta	Department of Neurology, Murakami Karindoh Hospital, Fukuoka, Japan
Tetsushi Takahashi	Department of Neurology, The Aichi Prefectural Federation of Agricultural Cooperatives for Health and Welfare, Kainan Hospital, Aichi, Japan
Hideyuki Matsumoto	Department of Neurology, Mitsui Memorial Hospital, Tokyo, Japan
Ohta Masahiko	Department of Neurology, Hyogo Prefectural Amagasaki General Medical Center, Hyogo, Japan
Akatsuki Kubota	Department of Neurology, The University of Tokyo, Tokyo, Japan

SECTION S2: PHARMACOKINETICS

1) Ropinirole concentration in blood

Blood samples were drawn at the following time points:

- After interim registration (Week 12)
- After the start of study treatment (Week 2)
- After dose escalation (Week 3–8)
- Before study drug administration at Week 13 and 24
- At the time of discontinuation

For subjects who proceeded to the open-label extension period, blood samples were drawn at similar time points as mentioned above and additional time points as listed below:

(A) Dose at the end of the double-blind period: 2 mg to 4 mg

At Weeks 26, 37, and 48 after the start of study treatment, or at the end of treatment

(B) Dose at the end of the double-blind period: 6 mg

At Weeks 27, 38, and 49 after the start of study treatment, or at the end of treatment

(C) Dose at the end of the double-blind period: 8 mg to 16 mg

At Weeks 28, 39, and 50 after the start of study treatment, or at the end of treatment

2) Ropinirole concentration in cerebrospinal fluid (CSF)

CSF samples were collected using lumbar puncture:

- Before the start of the first dose (3 days before to the day of the first dose)
- At Week 24 after the start of study treatment
- At the time of discontinuation

For subjects who proceeded to the open-label extension period, CSF samples were collected at similar time points as shown above, and additional time points as listed below.

(A) Dose at the end of the double-blind period: 2 mg to 4 mg

At Week 48 after the start of study treatment or at the end of treatment

(B) Dose at the end of the double-blind period: 6 mg

At Week 49 after the start of study treatment or at the end of treatment

(C) Dose at the end of the double-blind period: 8 mg to 16 mg

At Week 50 after the start of study treatment or at the end of treatment

(D) At the time of discontinuation after the final follow-up.

Shimadzu Tecno-Research, Inc. performed the measurements and submitted the results directly to the data management department to maintaining the blind of the study.

SECTION S3: SUPPLEMENTARY METHOD

The first draft of the manuscript was written by the first author and the co-authors provided medical writing assistance. K Pharma reviewed the manuscript and provided feedback to authors. Authors had full editorial control of the manuscript and provided their final approval of all content. All authors vouch for the accuracy and completeness of the data, for the fidelity of the trial to the protocol, and for the complete reporting of adverse events. Confidentiality agreements were in place between authors and K Pharma or GlaxoSmithKline (GSK).

Description of the similarity of interventions

GSK provided 2mg and 8mg control-released ropinirole hydrochloride in a light red white or reddish brown, oval and film-coated tablet. The placebo drug was matched to the study drug for taste, color, and size, and contained hypromerose, lactose hydrate, glycerin fatty acid ester, D-mannitol, sodium carmellose, hydrogenated oil, povidone, dextrin, magnesium stearate, light anhydrous silicic acid, yellow iron sesquioxide, titanium oxide, macrogol 400, and iron sesquioxide.

Genetic screening for familial ALS

We performed targeted sequencing by using next generation sequencer and our original ALS screening panel v2 (Total 63 genes: *ALS2*, *SETX*, *TUBA4A*, *PLEKHG5*, *DNAJB2*, *ANG*, *SIGMAR1*, *CHCHD10*, *SMN1*, *DYNC1H1*, *ATXN2*, *SOD1*, *TBK1*, *TRPV4*, *BICD2*, *C9ORF72*, *SPG11*, *EWSR1*, *VRK1*, *FBXO38*, *CHMP2B*, *TAF15*, *SQSTM1*, *HSPB1*, *ASAH1*, *DAO*, *TARDBP*, *SS18L1*, *HSPB3*, *EXOSC8*, *DCTN1*, *UBQLN2*, *GLE1*, *HSPB8*, *EXOSC3*, *FIG4*, *VAPB*, *GRN*, *ATL1*, *SLC52A3*, *FUS*, *VCP*, *ZNF512B*, *SPAST*, *SLC52A2*, *NEFH*, *ERBB4*, *ATP7A*, *AARS*, *HEXB*, *OPTN*, *HNRNPA1*, *BSCL2*, *REEP1*, *MAPT*, *PFN1*, *HNRNPA2B1*, *GARS*, *SLC5A7*, *PRPH*, *MATR3*, *IGHMBP2*, *UBA1*) and exome analysis to examine mutations related to ALS (Neurobiol Aging 2017;53:194.e1-194.e8.).

Post-hoc analyses

1) Ratio of change in the ALSFRS-R score every 4 weeks between the 12-week double-blind period (the latter of 12 weeks) and 24-week open label extension period assessments

The change in the ALSFRS-R score every 4 weeks during the double-blind period (the latter of 12 weeks) and the change in the ALSFRS-R score every 4 weeks during the 24-week open label extension period were calculated to obtain the Δ ALSFRS-R ratio by the following formula.

$$\Delta\text{ALSFRS-R ratio} = \frac{\text{Change in ALSFRS-R score every 4 weeks during the 24-week open label extension period}}{\text{Change in ALSFRS-R score every 4 weeks during the 12-week double-blind period (the latter of 12 weeks)}}$$

The change in the ALSFRS-R score every 4 weeks during the 12-week double-blind period (the latter of 12 weeks) and during the 24-week open label extension period were calculated based on the slope of a regression equation built by using the ALSFRS-R score measured for each subject as a response variable and the number of days from the start day of treatment at each measurement time point as an explanatory variable.

The analysis was performed on the FAS. Summary statistics (mean, SD, minimum, median, maximum, and 95%CI) were calculated for the measured value and the change from baseline in the Δ ALSFRS-R ratio during the 12-week double-blind period (the latter of 12 weeks) and during the 24-week open label extension period by treatment group. To confirm whether there was any significant change from the 12-week double-blind period (the latter of 12 weeks) to the 24-week open label extension period, a null hypothesis that the mean change from baseline at each time point was 0 was tested by treatment group using a one-sample t-test. In addition, to confirm whether there was any difference in the change between the groups, the least squares mean difference and the two-sided 95%CI were calculated using contrasts by an ANCOVA model with baseline value as a covariate. The baseline value was defined as the value on the day of the first dose of study treatment. If a significant deviation was found in the distribution of the dependent variable, a non-parametric approach was used as needed.

2) Composite endpoint as a sum of Z-transformed scores at 39 and 50 weeks

The analysis was performed on the FAS. Z-transformed scores at each time point were calculated using values of each item at Weeks 39 and 50 of the open label extension period and summed as the composite endpoint. Summary statistics (mean, SD, minimum, median, maximum, and 95%CI) were calculated for the composite endpoint at each time point and the change in the composite endpoint from 12 weeks after interim registration by treatment group. To confirm whether there was any difference in the change in the composite endpoints between the groups, MMRM analysis, with change from 12 weeks after interim registration as a dependent variable, was performed. In addition, summary statistics were calculated for the composite endpoint of Z-transformed scores obtained at Weeks 39 and 50 of the open label extension period. For differences between two groups, MMRM analysis was performed with the composite endpoint calculated from the change as a dependent variable. If a significant deviation was found in the distribution of the dependent variable, a non-parametric approach was used as needed.

3) The following items in the composite endpoint as a sum of Z-transformed scores

- ALSFRS-R sub-score of each domain (bulbar function, limb function, and respiratory function)
- Simple respiratory function test (FEV1, FEV6)
- Detailed respiratory function test (%FVC, FEV1%)

- MMT score (neck flexion, elbow flexion [right], elbow flexion [left], wrist extension [right], wrist extension [left], hip flexion [right], hip flexion [left], ankle dorsiflexion [right], ankle dorsiflexion [left])
- Quantitative muscle strength (neck flexion, elbow flexion [right], elbow flexion [left], wrist extension [right], wrist extension [left], hip flexion [right], hip flexion [left], ankle dorsiflexion [right], ankle dorsiflexion [left])
- Grip strength (right, left)
- Pinch strength (right, left)
- Modified Norris Scale (bulbar symptom score)
- Tongue pressure
- Body weight
- ALSAQ-40 score (physical mobility, ADL/independence, eating and drinking, communication, emotional functioning)
- Creatinine

The analysis was performed on the FAS. Summary statistics (mean, SD, minimum, median, maximum, and 95%CI) of all items were calculated for the double-blind period, open label extension period, and overall treatment period by treatment group. To confirm whether there was any significant change in each group, a null hypothesis that the change from baseline at each time point was 0 was tested by treatment group using a one-sample t-test. In addition, to confirm whether there was any difference in the change between the groups, MMRM analysis, with the change from baseline as a dependent variable, was performed for the double-blind period, open label extension period and overall treatment period. Baseline was defined as the day of the first dose of study treatment. If a significant deviation was found in the distribution of the dependent variable, a non-parametric approach was used if necessary.